沙利度胺对人肝癌细胞株SMMC-7721体内外肿瘤血管的影响

目的观察沙利度胺对人肝癌细胞株SMMC-7721体内外肿瘤血管的影响。方法体外实验：将不同浓度的沙利度胺作用于人肝癌细胞株SMMC-7721，采用ELISA方法测定细胞株VEGF分泌量变化。体内实验：首先建立肝癌细胞株SMMC-7721的荷瘤小鼠模型，应用免疫组化测定瘤体组织中微血管密度，ELISA法测定小鼠外周血VEGF表达。结果体外实验中随着沙利度胺药物浓度增加，VEGF含量逐渐下降：沙利度胺浓度从0μg／ml升至400μg／ml，VEGF值由（83．21±8．32）pg／ml降至（33．59±10．98）pg／ml；体内实验：成功建立了肝癌细胞株SMMC-7721的荷瘤小鼠模型，沙利度胺组小鼠外周血VEGF含量为（32．17±12．11）pg／ml，对照组为（69．35±17．56）pg／ml，在沙利度胺瘤体中微血管密度值为13．17±3．15，对照组为18．34±2．25，均有显著性差异（P〈0．01）。结论沙利度胺能抑制SMMC-7721细胞株及荷瘤鼠肿瘤血管的形成。

Effects of thalidomide on carcinoma angiogenesis of human hepatoma cell SMMC - 7721

Objective To observe the effects of thalidomide on antiangiogenic of Human Hepatoma Cell SMMC -7721 in vitro and vivo. Methods In vitro： The VEGF content of SMMC -7721 in cuture medium was tested by ELSIA. In vivo： Human liver cancer was transplanted subcutaneously in mice, then divided into two groups： control group and thalidomide group. VEGF protein level in serum was determined hy ELSIA. MVD was calculated by immunohistochemistry. Results In vitro： The VEGF content of SMMC -7721 in cuture medium with thalidomide was lower with the concentration increasing. The density of Thalidomide solution increased from 0 μg/ml to 400 μg/ml while the VEGF changed from （ 83.21±8.32） pg/ml to （33.59±10. 98 ） pg/ml. Conclusion The antiangiogenic of Human Hepatoma Cell SMMC - 7721 can be inhibited by thalidomide and the inhibition grew gradually with the increase of the density of thalidomide solution.